JP2015524849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524849A5 JP2015524849A5 JP2015527641A JP2015527641A JP2015524849A5 JP 2015524849 A5 JP2015524849 A5 JP 2015524849A5 JP 2015527641 A JP2015527641 A JP 2015527641A JP 2015527641 A JP2015527641 A JP 2015527641A JP 2015524849 A5 JP2015524849 A5 JP 2015524849A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- isolated
- disease
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 22
- 210000001808 exosome Anatomy 0.000 claims description 19
- 208000016192 Demyelinating disease Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 230000036542 oxidative stress Effects 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 108091034054 MiR-138 Proteins 0.000 claims description 5
- 108091030496 miR-138 stem-loop Proteins 0.000 claims description 5
- 108091063841 miR-219 stem-loop Proteins 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000006999 cognitive decline Effects 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 108091025686 miR-199a stem-loop Proteins 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683596P | 2012-08-15 | 2012-08-15 | |
| US61/683,596 | 2012-08-15 | ||
| PCT/US2013/055187 WO2014028763A1 (en) | 2012-08-15 | 2013-08-15 | Exosome-based therapeutics against neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524849A JP2015524849A (ja) | 2015-08-27 |
| JP2015524849A5 true JP2015524849A5 (enExample) | 2016-09-29 |
Family
ID=50101510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527641A Pending JP2015524849A (ja) | 2012-08-15 | 2013-08-15 | 神経変性疾患に対するエキソソームに基づく治療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10231997B2 (enExample) |
| EP (1) | EP2885414B1 (enExample) |
| JP (1) | JP2015524849A (enExample) |
| AU (1) | AU2013302526B2 (enExample) |
| CA (1) | CA2882248A1 (enExample) |
| WO (1) | WO2014028763A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2014028763A1 (en) * | 2012-08-15 | 2014-02-20 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| TWI788704B (zh) * | 2013-10-24 | 2023-01-01 | 美商納諾索米克斯公司 | 分析個體樣品之方法 |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| US10624929B2 (en) * | 2014-05-18 | 2020-04-21 | Children's Medical Center Corporation | Methods and compositions relating to exosomes |
| EP3146346A4 (en) * | 2014-05-23 | 2018-03-21 | Georgetown University | Exosome and lipid biomarkers for memory loss |
| WO2016111530A1 (ko) * | 2015-01-05 | 2016-07-14 | 권영아 | 루테리온을 이용한 암세포의 텔로머라아제 억제방법 |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| SG11201804117XA (en) * | 2015-11-18 | 2018-06-28 | Univ Georgia | Neural cell extracellular vessicles |
| US12364661B2 (en) | 2015-11-20 | 2025-07-22 | The Regents Of The University Of California | Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| US11243215B2 (en) | 2016-01-14 | 2022-02-08 | The Regents Of The University Of California | 3D-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids |
| KR102805970B1 (ko) | 2016-03-02 | 2025-05-09 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 매트릭스가 결합된 나노소낭 및 그의 용도 |
| EP3423070B1 (en) * | 2016-03-03 | 2022-05-04 | Henry Ford Health System | 3-d collagen scaffold-generated exosomes and uses thereof |
| WO2018035204A1 (en) * | 2016-08-16 | 2018-02-22 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| US12622876B2 (en) | 2016-08-22 | 2026-05-12 | Lonza Sales Ag | Methods of suppressing delivery of exosomes to liver and spleen |
| US20200046766A1 (en) | 2016-10-13 | 2020-02-13 | Vbc Holdings Llc | Cancer stem cell exosomes |
| CA3042360A1 (en) | 2016-11-03 | 2018-05-11 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| ES3035746T3 (en) * | 2016-11-23 | 2025-09-08 | Mayo Found Medical Education & Res | Particle-mediated delivery of inhibitory rna |
| EP3568020A4 (en) * | 2017-01-12 | 2020-11-11 | Duke University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINIZING CONDITIONS |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| JP7280624B2 (ja) | 2017-04-03 | 2023-05-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル（ｄｎｖ） |
| WO2018208971A1 (en) * | 2017-05-10 | 2018-11-15 | University Of Louisville Research Foundation, Inc. | Compositions comprising engineered embryonic stem cell-derived exosomes and method of use therefor |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| CN108103026B (zh) * | 2017-12-05 | 2020-12-22 | 四川省肿瘤医院 | 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法 |
| CN107988153B (zh) * | 2017-12-15 | 2021-05-18 | 英科博雅生命科技有限公司 | 人脐带血间充质干细胞源分离外泌体的方法和使用的试剂 |
| US12017066B2 (en) | 2018-01-05 | 2024-06-25 | Mayo Foundation For Medical Education And Research | Modulation of extracellular vesicles with electrical stimulation |
| US12521418B2 (en) | 2018-04-30 | 2026-01-13 | Children's Medical Center Corporation | Mesenchymal stromal cell exosomes and uses thereof |
| US11278575B2 (en) | 2018-07-12 | 2022-03-22 | Duke University | Compositions and methods for the treatment of demyelinating conditions |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US20200108241A1 (en) * | 2018-10-04 | 2020-04-09 | Synaptec Network, Inc. | Systems and Methods for Delivering Exosomes Through the Blood-Brain Barrier |
| EP4491229A3 (en) | 2019-02-08 | 2025-05-14 | CureVac SE | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| WO2020247432A1 (en) | 2019-06-04 | 2020-12-10 | Thomas Jefferson University | Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis |
| JP7372518B2 (ja) * | 2019-06-27 | 2023-11-01 | 国立大学法人山口大学 | 骨髄由来間葉系幹細胞の培養方法 |
| KR20220041131A (ko) * | 2019-07-26 | 2022-03-31 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 항산화제 및 항바이러스 조성물 및 방법 |
| CN111117964B (zh) * | 2019-07-30 | 2020-12-01 | 段海峰 | 一种肿瘤来源外泌体及其制备方法和用途 |
| TR201911667A2 (tr) | 2019-08-01 | 2021-02-22 | Univ Yeditepe | Hücrelerde oluşan protein birikintilerinden kaynaklanan hastalıkların tedavisi için kullanılan bitki eksozomları. |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| KR20220131513A (ko) * | 2019-10-16 | 2022-09-28 | 더 존스 홉킨스 유니버시티 | 신경병 질환의 치료를 위한 세포외 소낭 기반 제제 및 방법 |
| CN112972702A (zh) * | 2019-12-17 | 2021-06-18 | 南京大学 | 用于治疗耐药菌感染的外泌体制剂 |
| IL294408A (en) * | 2019-12-31 | 2022-08-01 | Chase Therapeutics Corp | Kinases as biomarkers for neurodegenerative conditions |
| US20230097907A1 (en) * | 2020-01-27 | 2023-03-30 | Mantra Bio, Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
| WO2021194902A1 (en) * | 2020-03-21 | 2021-09-30 | Florica Therapeutics, Inc. | Neuronal diencephalon stem cells, preparation and uses for treatment and prevention of hormonal disorders and other diseases |
| CN111876388A (zh) * | 2020-07-24 | 2020-11-03 | 赛瑞诚(苏州)生物科技有限公司 | 一种骨和骨组织靶向外泌体及其制备方法和应用 |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| US20220296645A1 (en) * | 2021-03-22 | 2022-09-22 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo |
| WO2023283218A2 (en) * | 2021-07-07 | 2023-01-12 | University Of Florida Research Foundation, Incorporated | Light-induced cellular production of immune functional extracellular vesicles |
| CN116098921A (zh) * | 2021-11-10 | 2023-05-12 | 南京大学 | 一种具有哺乳动物大脑系统抗衰作用的生物制品及其制备方法和应用 |
| CN116440168A (zh) * | 2022-01-06 | 2023-07-18 | 南京大学 | 一种生物制品及其制备方法和其在制备抗衰延寿产品中的应用 |
| CN115006427A (zh) * | 2022-05-31 | 2022-09-06 | 尧舜泽生物医药(南京)有限公司 | 骨髓间充质干细胞外泌体在治疗帕金森病中的应用 |
| EP4622654A1 (en) * | 2022-11-23 | 2025-10-01 | Exomed Pty Ltd | Method for preventing or treating age related conditions using extracellular vesicles derived from a young mammal |
| WO2024186630A1 (en) * | 2023-03-03 | 2024-09-12 | Henry Ford Health System | Use of extracellular vesicles for the treatment of cancer |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| US20040241176A1 (en) | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| US7689196B2 (en) | 2002-06-26 | 2010-03-30 | Qualcomm Incorporated | Timer-based sleep for terminals in wireless communication systems |
| US20060147946A1 (en) * | 2004-01-27 | 2006-07-06 | Pinchas Akiva | Novel calcium channel variants and methods of use thereof |
| WO2005111211A2 (en) * | 2004-05-14 | 2005-11-24 | Rosetta Genomics Ltd. | Micronas and uses thereof |
| EP2613149B1 (en) | 2007-07-25 | 2014-09-17 | University Of Louisville Research Foundation, Inc. | Exosome-associated microRNA as a diagnostic marker |
| GB2464888C (en) * | 2007-08-10 | 2025-03-19 | Univ Wayne State | Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system |
| PL2254586T3 (pl) | 2008-02-22 | 2015-09-30 | Agency For Science Tech And Research Astarstar | Cząstki mezenchymalnych komórek macierzystych |
| CA2743211A1 (en) | 2008-11-12 | 2010-05-20 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods and systems of using exosomes for determining phenotypes |
| DK2734634T3 (da) | 2011-07-22 | 2019-10-21 | Univ Chicago | Igf-1 til anvendelse til behandling af migræne |
| WO2014028763A1 (en) | 2012-08-15 | 2014-02-20 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
-
2013
- 2013-08-15 WO PCT/US2013/055187 patent/WO2014028763A1/en not_active Ceased
- 2013-08-15 AU AU2013302526A patent/AU2013302526B2/en active Active
- 2013-08-15 JP JP2015527641A patent/JP2015524849A/ja active Pending
- 2013-08-15 CA CA2882248A patent/CA2882248A1/en not_active Abandoned
- 2013-08-15 EP EP13829748.6A patent/EP2885414B1/en active Active
- 2013-08-15 US US14/420,680 patent/US10231997B2/en active Active
-
2019
- 2019-01-28 US US16/259,563 patent/US11369634B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Biogenesis, composition and potential therapeutic applications of mesenchymal stem cells derived exosomes in various diseases | |
| JP2025108487A (ja) | 幹細胞の培養及び治療のための培地、方法、細胞、及び分泌因子 | |
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| CA2752694A1 (en) | Synthetic rna-based agonists of tlr7 | |
| NZ628328A (en) | Rna formulation for immunotherapy | |
| Zheng et al. | The paradoxical role of tumor-infiltrating immune cells in lung cancer | |
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| JP2019504105A5 (enExample) | ||
| NZ591326A (en) | An extended release pharmaceutical composition of entacapone or salts thereof | |
| JP2015512418A5 (enExample) | ||
| NZ773177A (en) | Neuroactive steroid formulations and methods of treating cns disorders | |
| HK1205156A1 (en) | Cyclodextrin-based polymers for therapeutic delivery | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| JP2016508123A5 (enExample) | ||
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| RU2021135194A (ru) | Способы и аппараты для подготовки клеточных популяций для клеточной терапии | |
| MX376783B (es) | Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. | |
| Xu et al. | The enhancing effect of DNA tetrahedron-based lactoferrin as an assembled adjuvant in immunotherapy | |
| EP4365289A3 (en) | Rna interference delivery formulation and methods for malignant tumors | |
| Taheraghdam et al. | Intravenous dexamethasone versus morphine in relieving of acute migraine headache | |
| BR112016015281A8 (pt) | uso de um filtro em linha intravenoso, e método para preparação de um conjunto de infusão | |
| Qu et al. | Polyphenolic nanobattery charged adoptive macrophages for sepsis immunotherapy |